In the event of a dog bite, a person needs more than just the rabies vaccine. Experts highlight the importance of ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...